A5084514047- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Coronary Interventions and Diagnostics
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Health Systems, Economic Evaluations, Quality of Life
- Antiplatelet Therapy and Cardiovascular Diseases
- Statistical Methods in Clinical Trials
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac, Anesthesia and Surgical Outcomes
- Diabetes Treatment and Management
- Lipoproteins and Cardiovascular Health
- Aortic aneurysm repair treatments
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Advanced Causal Inference Techniques
- Venous Thromboembolism Diagnosis and Management
- Medication Adherence and Compliance
- Cardiac Arrest and Resuscitation
- Mechanical Circulatory Support Devices
- Hemodynamic Monitoring and Therapy
- ECG Monitoring and Analysis
- Acute Ischemic Stroke Management
University of Alberta
2016-2025
Canadian VIGOUR Centre
2016-2025
Alberta Hospital Edmonton
2011-2024
Clinical Research Institute
2008-2021
Alaska Heart and Vascular Institute
2021
Duke University
2021
Uppsala University
2011-2012
University of Sheffield
2011-2012
University of British Columbia
2008-2012
University Health Network
2012
Patients undergoing major vascular surgery are at increased risk of perioperative mortality due to underlying coronary artery disease. Inhibitors the 3-hydroxy-3-methylglutaryl coenzyme A (statins) may reduce through improvement lipid profile, but also stabilization plaques on wall.To evaluate association between statin use and mortality, we performed a case-controlled study among 2816 patients who underwent from 1991 2000 Erasmus Medical Center. Case subjects were all 160 (5.8%) died during...
To examine the incidence of and propensity for non-culprit interventions performed at time primary percutaneous coronary intervention (PCI) its association with 90-day outcomes.We examined incidence, for, associated outcomes following PCI among ST-elevation myocardial infarction patients multi-vessel artery disease (MVD). Of 5373 who underwent in APEX-AMI trial, 2201 had MVD. those, 217 (9.9%) non-infarct-related arteries (IRA) PCI, whereas 1984 (90.1%) IRA alone. Ninety-day death...
Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary intervention (PCI) would facilitate appropriate care expedite hospital discharge. Thus, we determined the prognostic importance various measures ST-segment-elevation recovery PCI in a large, contemporary cohort patients with ST-elevation infarction.We analyzed ECG data describing magnitude extent ST-segment elevation...
Little is known regarding consequences of frailty in patients with acute coronary syndrome (ACS). We assessed the associations and outcomes ACS who were participating a clinical trial. The TaRgeted platelet Inhibition to cLarify Optimal strateGy medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial randomized 9326 planned for medical management prasugrel or clopidogrel. primary endpoint was composite cardiovascular death, myocardial infarction (MI), stroke over period 30 months. A...
The purpose of this study was to examine the treatment effect vericiguat in relation N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at randomization.Vericiguat compared with placebo reduced primary outcome cardiovascular death (CVD) or heart failure hospitalization (HFH) patients HF ejection fraction (HFrEF) VICTORIA (A Study Vericiguat Participants With Heart Failure Reduced Ejection Fraction) trial. Because an interaction existed between and according pre-specified quartiles...
Despite evidence that guideline-directed medical therapy (GDMT) improves outcomes in patients with heart failure (HF) and reduced ejection fraction, many are undertreated. The Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) trial tested whether a strategy of using target concentrations N-terminal pro-brain natriuretic peptide (NT-proBNP) to guide optimization GDMT could improve outcomes.To examine for HF GUIDE-IT potential reasons why the intervention did not...
Aim Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in VICTORIA (Vericiguat Global Study Patients Heart Failure Reduced Ejection Fraction) trial. Methods and results Key background characteristics were evaluated 5050 randomized categorized into three cohorts reflecting their index worsening HF event. Differences within population assessed compared PARADIGM‐HF (Prospective comparison ARNI ACEI to Determine Impact on Mortality...
ST-segment-elevation myocardial infarction (STEMI) guidelines recommend pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is unavailable. Full-dose tenecteplase associated with an increased risk of intracranial hemorrhage in older patients. Whether half-dose effective and safe patients STEMI unknown.
Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in VICTORIA trial. It is unknown if these benefits are related to reverse left ventricular (LV) remodelling with vericiguat patients HF ejection fraction (HFrEF). The aim this study was compare effects versus placebo on LV structure and function after 8 months therapy HFrEF.Standardized transthoracic echocardiography (TTE) performed at baseline a subset HFrEF VICTORIA....
Patient sex has been shown to differentially affect mortality from unstable angina (UA) and acute myocardial infarction (AMI). However, our knowledge, no prior population-based studies have examined both cohorts simultaneously explain this intriguing variation. Hence, we undertook explore differences in 5-year after UA AMI.We used an administrative database of 22 967 patients with AMI 8441 discharged care hospitals Alberta between April 1, 1993, March 31, 2000.Women were older more baseline...
AimsControversy exists regarding the early use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The Assessment Pexelizumab Acute Myocardial Infarction (APEX-AMI) trial provides a unique opportunity to examine vs. late or non-use GPIs large STEMI cohort treated PCI.